Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Trodelvy
Biotech
AstraZeneca, Daiichi ADC fails to improve breast cancer survival
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate Dato-DXd has again failed to improve overall survival in a phase 3 trial.
Nick Paul Taylor
Sep 23, 2024 7:23am
Former Immunomedics CFO pleads guilty to securities fraud
May 18, 2023 9:08am
Girlfriend of ex-Immunomedics CFO pleads guilty to fraud
Jun 23, 2022 10:21am
Former Immunomedics CFO indicted on insider trading charges
May 11, 2022 2:20pm
